The AccessDx PGx Profile features:
PGx for [Specialty]
Providers administering care for oncology patients may benefit greatly from the complex medication nuance present in polypharmacy.
- Comprehensive multispecialty panels covering 16+ therapeutic areas
- Provides actionable high-evidence drug-gene interaction insights based on CPIC, FDA, and DPWG guidance
- Ability to detect complex structural variations, enabling the identification of both common and rare ethno-specific variations – including many targets not routinely detected by other US laboratories
- Developed and validated by a team of leading PGx experts and researchers
Interesting statistic or fact about the product.
Option for statistics here
Testing options for [specialty] providers
Offering Header – Comprehensive Panel
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Offering Header – Focused Panel
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Offering Header – Single-gene DPYD Testing
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
PGx Testing May Impact Treatment using:
Oncology Medications
Behavioral Health
Gastroenterology Medications
Hyperuricemia Management
Infection Management
Neurology
Pain Management
Rheumatology & Autoimmune Disorders
Urology
PGx Use in [specialty] Resources
Government and Scientific Resources
AccessDx PGxperts™ Articles
- Journal of Clinical Pathways: Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice
- Healthcare Business Today: Pharmacogenomics in Oncology: Unlocking Value, Safety, and ROI for Healthcare Systems
- MedCity News, Drug-Gene Testing: Key to Safer Cancer Treatment
- Journal of Clinical Pathways, FDA Highlights Risks Associated With DPD Deficiency, Advises Testing Before Treatment
- Pharmaceutical Executive, Screening for DPD: Q&A with Kristine Ashcraft
- Journal of Clinical Pathways, “Implementing PGx Testing in Oncology: Best Practices, Barriers, and Benefits.”
- Journal of Clinical Pathways, “Recommendations for Standardizing DPYD Pharmacogenomic Testing.”

